Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.
Du Z, Weinhold N, Song GC, Rand KA, Van Den Berg DJ, Hwang AE, Sheng X, Hom V, Ailawadhi S, Nooka AK, Singhal S, Pawlish K, Peters ES, Bock C, Mohrbacher A, Stram A, Berndt SI, Blot WJ, Casey G, Stevens VL, Kittles R, Goodman PJ, Diver WR, Hennis A, Nemesure B, Klein EA, Rybicki BA, Stanford JL, Witte JS, Signorello L, John EM, Bernstein L, Stroup AM, Stephens OW, Zangari M, Van Rhee F, Olshan A, Zheng W, Hu JJ, Ziegler R, Nyante SJ, Ingles SA, Press MF, Carpten JD, Chanock SJ, Mehta J, Colditz GA, Wolf J, Martin TG, Tomasson M, Fiala MA, Terebelo H, Janakiraman N, Kolonel L, Anderson KC, Le Marchand L, Auclair D, Chiu BC, Ziv E, Stram D, Vij R, Bernal-Mizrachi L, Morgan GJ, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Conti DV, Haiman CA, Cozen W. Du Z, et al. Among authors: nooka ak. Blood Adv. 2020 Jan 14;4(1):181-190. doi: 10.1182/bloodadvances.2019000491. Blood Adv. 2020. PMID: 31935283 Free PMC article.
Supportive therapies in multiple myeloma.
Gleason C, Nooka A, Lonial S. Gleason C, et al. J Natl Compr Canc Netw. 2009 Oct;7(9):971-9. doi: 10.6004/jnccn.2009.0064. J Natl Compr Canc Netw. 2009. PMID: 19878640 Review.
Improving induction therapy in multiple myeloma.
Nooka A, Gleason C, Lonial S. Nooka A, et al. Curr Hematol Malig Rep. 2010 Jul;5(3):119-28. doi: 10.1007/s11899-010-0057-7. Curr Hematol Malig Rep. 2010. PMID: 20449692 Review.
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
Lonial S, Kaufman J, Tighiouart M, Nooka A, Langston AA, Heffner LT, Torre C, McMillan S, Renfroe H, Harvey RD, Lechowicz MJ, Khoury HJ, Flowers CR, Waller EK. Lonial S, et al. Clin Cancer Res. 2010 Oct 15;16(20):5079-86. doi: 10.1158/1078-0432.CCR-10-1662. Epub 2010 Aug 25. Clin Cancer Res. 2010. PMID: 20739431 Clinical Trial.
Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.
Harvey RD, Kaufman JL, Johnson HR, Nooka A, Vaughn L, Flowers CR, Khoury HJ, Lechowicz MJ, Langston AA, Lonial S, Waller EK. Harvey RD, et al. Biol Blood Marrow Transplant. 2013 Sep;19(9):1393-5. doi: 10.1016/j.bbmt.2013.06.003. Epub 2013 Jun 10. Biol Blood Marrow Transplant. 2013. PMID: 23764455 Free article. Clinical Trial.
178 results